Want to see NKTR full AI Analyst Report?
NKTR Stock Chart & Stats
$84.86
-$0.04(-3.36%)
At close: 4:00 PM EST
$84.86
-$0.04(-3.36%)
Day’s Range― - ―
52-Week Range$21.02 - $109.00
Previous CloseN/A
Volume706.47K
Average Volume (3M)1.09M
Market Cap
$2.19B
Enterprise Value$1.35K
Total Cash (Recent Filing)$568.60M
Total Debt (Recent Filing)$143.43M
Price to Earnings (P/E)―
Beta3.60
Next Earnings
Aug 06, 2026EPS Estimate
-1.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.42
Shares Outstanding33,786,034
10 Day Avg. Volume829,171
30 Day Avg. Volume1,089,086
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)7.94
Price to Sales (P/S)12.91
P/FCF Ratio-3.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$154.33Price Target Upside81.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-8.9
Revenue Forecast (FY)$41.18M
Bulls Say, Bears Say
Bulls Say
Phase IIb Efficacy And Clear Phase III PathDurable, deepening Phase IIb efficacy that produced large increases in complete clearance metrics provides substantive clinical validation of the mechanism. That durability and clear Phase III design reduces scientific risk, materially strengthening the long-term chance of successful registration and commercialization.
Materially Strengthened Balance Sheet And Multi-year RunwayPro forma cash >$1B and runway into Q3 2028 meaningfully de-risks near-term program funding. This durable liquidity enables initiation and execution of global Phase III programs without immediate financing pressure, supporting sustained R&D investment and operational continuity through pivotal milestones.
Differentiated Mechanism With Favorable Safety ProfileA Treg‑stimulating MOA with a cleaner safety profile versus JAKs offers a durable competitive advantage for chronic indications, reducing monitoring burdens and widening patient suitability. Safer long‑term tolerability can support broader adoption, better retention, and stronger commercial positioning.
Bears Say
Persistent Cash Burn And Negative Free Cash FlowSustained negative operating and free cash flow near -$204M TTM is a structural constraint: even with recent financings, ongoing Phase III spend will continue cash outflows. Over the medium term this necessitates additional financing or program prioritization, increasing dilution or operational risk.
Large Operating And Net Losses RemainDespite high gross margins, extreme negative operating and net margins signal the business is far from self-sustaining. Continued heavy losses imply lengthy dependence on external capital and that commercial profitability will require successful product launches and scale, a multi-period execution risk.
Regulatory And Global Execution Risks For Registrational TrialsUnresolved regulatory alignment for the AA registrational path and the complexity of large global Phase IIIs create durable timing, design and cost risk. Potential changes to endpoints, required trials, or enrollment rates can delay approval, raise expenses, or necessitate additional studies.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was $21.02 and its highest was $109.00 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $2.19B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on May 07, 2026. The company reported -$1.82 earnings per share for the quarter, missing the consensus estimate of -$1.582 by -$0.238.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -1.98.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 33,786,034 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$1.82 in its last earnings report, missing expectations of -$1.582. Following the earnings report the stock price went down -1.775%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in NKTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$154.33 (81.87% Upside)
$154.33 (81.87% Upside)
Blogger Sentiment
Bullish
NKTR Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 377.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $42.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
159.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
197.87%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
NKTR Stock 12 Month Forecast
Average Price Target
$154.33
▲(81.87% Upside)
Technical Analysis
Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
2.98% Insiders
13.81% Mutual Funds
0.08% Other Institutional Investors
70.23% Public Companies and
Individual Investors